Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum‐based chemotherapy-Reference-Cited by-同舟云学术

Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum‐based chemotherapy

Published:2022-02-10 Issue:5 Volume:48 Page:1248-1254
ISSN:1341-8076
Container-title:Journal of Obstetrics and Gynaecology Research
language:en
Short-container-title:J of Obstet and Gynaecol

Author:

Nakazawa Hiroshi¹^ORCID,Nagao Shoji²^ORCID,Narita Moyu¹,Shibutani Takashi¹,Jimi Tomoatsu¹,Yano Hiroko¹,Kitai Miho¹^ORCID,Shiozaki Takaya¹,Yamaguchi Satoshi¹

Affiliation:

1. Department of Gynecologic Oncology Hyogo Cancer Center Akashi Hyogo Japan

2. Department of Obstetrics and Gynecology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan

Publisher

Wiley

Subject

Obstetrics and Gynecology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jog.15184

Reference14 articles.

1. Annual report of the Committee on Gynecologic Oncology , the Japan Society of Obstetrics and Gynecology : Annual patient report for 2017 and annual treatment report for 2012

2. Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer

3. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

4. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

5. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance;Gynecologic Oncology Reports;2024-10

2. Effects of PARP Inhibitors on Subsequent Platinum-Based Chemotherapy in Patients with Recurrent Ovarian Cancer;Cancers;2024-07-25

3. Ovarian cancer: Diagnosis and treatment strategies (Review);Oncology Letters;2024-07-18

4. Subsequent management and outcomes after first-line PARP inhibitors progression in ovarian cancer patients;Journal of Ovarian Research;2024-04-01

5. New horizons for platinum-resistant ovarian cancer: insights from the 2023 American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology (ESMO) Annual Meetings;International Journal of Gynecologic Cancer;2023-12-14